Polyphosphoric acids, esters with triethanolamine, sodium salts

Acute Toxicity: dermal

Administrative data

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Study period:

.The study was performed between 20 July 2011 and 17 August 2011.

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Study conducted to GLP and in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not effect the quality of the relevant results.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2011

Report date:

2011

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.3 (Acute Toxicity (Dermal))

Deviations:

no

Test guideline 3

Qualifier:

according to guideline

Guideline:

EPA OPPTS 870.1200 (Acute Dermal Toxicity)

Deviations:

no

Test guideline 4

Qualifier:

according to guideline

Guideline:

other: Japanese Ministry of Agriculture, Forestry and Fisheries (MAFF), Testing Guidelines for Toxicology Studies, 12 NohSan No. 8147, amended 26 June 2001

Deviations:

no

Test guideline 5

Qualifier:

according to guideline

Guideline:

other: Japanese Ministry of Health and Welfare, 1992

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

standard acute method

Limit test:

yes

Test material

Test material information

Constituent 1

Reference substance name:

Polyphosphoric acids, esters with triethanolamine, sodium salts

EC Number:

268-625-3

EC Name:

Polyphosphoric acids, esters with triethanolamine, sodium salts

Cas Number:

68131-72-6

Molecular formula:

Not applicable (a generic molecular formula cannot be provided for this specific UVCB substance)

IUPAC Name:

Polyphosphoric acids, esters with triethanolamine, sodium salts

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS- Source: Five male and five female Wistar (RccHan:WIST) strain rats were supplied by Harlan Laboratories UK Ltd., Oxon, UK. - Age at study initiation: Eight to twelve weeks of age.- Weight at study initiation: At the start of the study the animals weighed at least 200g. The weight variation did not exceed ±20% of the mean weight for each sex.- Fasting period before study: None.- Housing: The animals were housed in suspended solid floor polypropylene cages furnished with woodflakes. The animals were housed individually during the 24 Hour exposure period and in groups of five, by sex, for the remainder of the study. - Diet (e.g. ad libitum): Free access to food (2014C Teklad Global Rodent diet supplied by Harlan Laboratories UK Ltd., Oxon, UK) was allowed throughout the study. - Water (e.g. ad libitum): Free access to mains drinking water was allowed throughout the study- Acclimation period: At least five days.ENVIRONMENTAL CONDITIONS- Temperature (°C): 19 to 25°C - Humidity (%): 30 to 70%Any occasional deviations from these targets were considered not to have affected the purpose or integrity of the study. - Air changes (per hr): At least fifteen changes per hour- Photoperiod (hrs dark / hrs light): Lighting was controlled by a time switch to give twelve hours continuous light (06:00 to 18:00) and twelve hours darkness.

Administration / exposure

Type of coverage:

semiocclusive

Vehicle:

unchanged (no vehicle)

Details on dermal exposure:

TEST SITEOn the day before treatment the back and flanks of each animal were clipped free of hair.Using available information on the toxicity of the test item, a group of five male and five female rats was treated with the test item at a dose level of 2393 mg/kg (equivalent to 2000 mg active ingredient/kg bodyweight).The calculated volume of test item, as received, was applied as evenly as possible to an area of shorn skin (approximately 10% of the total body surface area) using a graduated syringe. A piece of surgical gauze was placed over the treatment area and semi-occluded with a piece of self-adhesive bandage. The animals were caged individually for the 24-Hour exposure period. Shortly after dosing the dressings were examined to ensure that they were securely in place.REMOVAL OF TEST SUBSTANCEAfter the 24 Hour contact period the bandage was carefully removed and the treated skin and surrounding hair wiped with cotton wool moistened with distilled water to remove any residual test item. The animals were returned to group housing for the remainder of the study period.

Duration of exposure:

24 hour contact period.

Doses:

Using available information on the toxicity of the test item, a group of five male and five female rats was treated with the test item at a dose level of 2393 mg/kg (equivalent to 2000 mg active ingredient/kg bodyweight).For the purpose of the study test concentrations were adjusted to allow for the stated water/glycol content (16.4%) of the test item. The test item was weighed out according to each animal’s individual bodyweight.

No. of animals per sex per dose:

Five males and five females at 2393 mg/kg (equivalent to 2000 mg active ingredient/kg bodyweight).

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days - Frequency of observations and weighing: The animals were observed for deaths or overt signs of toxicity ½, 1, 2 and 4 hours after dosing and subsequently once daily for fourteen days.After removal of the dressings and subsequently once daily for fourteen days, the test sites were examined for evidence of primary irritation and scored according to the Draize scale (see evaluation of skin reactions).Any other skin reactions, if present were also recorded.Individual bodyweights were recorded prior to application of the test item on Day 0 and on Days 7 and 14. - Necropsy of survivors performed: yesAt the end of the study the animals were killed by cervical dislocation. All animals were subjected to gross necropsy. This consisted of an external examination and opening of the abdominal and thoracic cavities. The appearance of any macroscopic abnormalities was recorded. No tissues were retained.

Results and discussion

Preliminary study:

No preliminary study.

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 393 mg/kg bw

Based on:

test mat.

Remarks on result:

other: equivalent to 2000 mg active ingredient/kg bodyweight

Mortality:

There were no deaths.

Clinical signs:

other: There were no signs of systemic toxicity.

Gross pathology:

No abnormalities were noted at necropsy.

Other findings:

Dermal Reactions:There were no signs of dermal irritation.

Any other information on results incl. tables

Individual Bodyweights and Weekly Bodyweight Changes

Dose Level mg/kg	Animal Number and Sex	Bodyweight (g) at Day			Bodyweight Change (g) During Week
		0	7	14	1	2
2393*	1-0 Male	230	263	274	33	11
	1-1 Male	245	267	300	22	33
	1-2 Male	288	297	337	9	40
	1-3 Male	253	282	307	29	25
	1-4 Male	251	271	303	20	32
	2-0 Female	216	218	222	2	4
	2-1 Female	208	213	224	5	11
	2-2 Female	209	213	219	4	6
	2-3 Female	215	216	220	1	4
	2-4 Female	208	212	222	4	10

*=      Equivalent to 2000 mg active ingredient/kg bodyweight

Applicant's summary and conclusion

Interpretation of results:

not classified

Remarks:

Migrated informationCriteria used for interpretation of results: EU

Conclusions:

The acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2393 mg/kg bodyweight (equivalent to 2000 mg active ingredient/kg bodyweight).The test item does not meet the criteria for classification according to the Classification, Labelling and Packaging Regulation or the Globally Harmonised Classification System.

Executive summary:

Introduction.

The study was performed to assess the acute dermal toxicity of the test item in the Wistar strain rat. The method was designed to be compatible with the following:

- OECD Guidelines for the Testing of Chemicals No. 402 “Acute Dermal Toxicity” (adopted 24 February 1987)

- Method B3 Acute Toxicity (Dermal) of Commission Regulation (EC) No. 440/2008

- United States Environmental Protection Agency Health Effects Test Guidelines OPPTS 870.1200 Acute Dermal Toxicity August 1998

- Japanese Ministry of Agriculture, Forestry and Fisheries (MAFF), Testing Guidelines for Toxicology Studies, 12 NohSan No. 8147, amended 26 June 2001

- Japanese Ministry of Health and Welfare, 1992

Method. 

A group of ten animals (five males and five females) was given a single, 24 hour, semi‑occluded dermal application of the test item to intact skin at a dose level of 2393 mg/kg bodyweight (equivalent to 2000 mg active ingredient/kg bodyweight). Clinical signs and bodyweight development were monitored during the study. All animals were subjected to gross necropsy.

Mortality. 

There were no deaths.

Clinical Observations. 

There were no signs of systemic toxicity.

Dermal Irritation. 

There were no signs of dermal irritation.

Bodyweight. 

All animals showed expected gains in bodyweight over the study period.

Necropsy. 

No abnormalities were noted at necropsy.

Conclusion. 

The acute dermal median lethal dose (LD₅₀) of the test item in the Wistar strain rat was found to be greater than 2393 mg/kg bodyweight (equivalent to 2000 mg active ingredient/kg bodyweight).

The test item does not meet the criteria for classification according to the Classification, Labelling and Packaging Regulation or theGlobally Harmonised Classification System.